Search

Displaying results 3381 - 3390 of 8700 in total
  1. Drug

    Raxtozinameran

    go.drugbank.com/drugs/DB18228
    ApprovedInvestigational

    Raxtozinameran is also known as Pfizer-BioNTech COVID-19 Vaccine and Comirnaty. It works by binding to the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is a transmembrane glycoprotein that play...

  2. Drug

    Bavituximab

    go.drugbank.com/drugs/DB05136
    Investigational

    Bavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections.

  3. Drug

    Sodium phosphate, monobasic, unspecified form

    go.drugbank.com/drugs/DB14503
    Approved

    Mixtures: Fleet for Children, Fleet for Children
  4. Drug

    Plecanatide

    go.drugbank.com/drugs/DB13170
    ApprovedInvestigational

    Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).

    Categories: Drugs for Constipation
  5. Drug

    Phthalylsulfathiazole

    go.drugbank.com/drugs/DB13248
    Approved

    It was used as an antibiotic for bowel surgery, and for infections of the colon [A175006].

  6. Drug

    Enprofylline

    go.drugbank.com/drugs/DB00824
    ApprovedWithdrawn

    Long-term enprofylline administration may be associated with elevation in liver enzyme levels and unpredictable blood levels.

    Categories: Purinergic P1 Receptor Antagonists, Adenosine A2 Receptor Antagonists
  7. Drug

    Trifarotene

    go.drugbank.com/drugs/DB12808
    ApprovedInvestigational

    Trifarotene is a topical retinoid cream used in the treatment of acne vulgaris that was first approved for use in the United States in October 2019.

    Categories: Anti-Acne Preparations for Topical Use, Retinoids for Topical Use in Acne
  8. Drug

    GI-5005

    go.drugbank.com/drugs/DB05942
    Investigational

    GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection. … Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.

  9. Drug

    Zimlovisertib

    go.drugbank.com/drugs/DB15143
    Investigational

    PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).

  10. Drug

    Virus Specific T-Cell

    go.drugbank.com/drugs/DB15735
    Investigational

    Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. … Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and activation.